There's more than one way to build a biotech
From The Top Line · · 16 min
This plays from the publisher's own server. We do not host a copy.
Description
As biotech companies continue to navigate a challenging funding environment, Axiom Biosciences is taking an unconventional approach to raising capital and developing new therapies.
The company is pursuing a public listing in Hong Kong, with ambitions to eventually list on the Nasdaq. Meanwhile, it's developing several drug delivery platforms, including a stem cell therapy approach that doesn't rely on genetic modification.
In this episode of "The Top Line," Fierce Biotech's Marissa Russo speaks with Axiom founder and CEO Remo Moomiaie-Qajar about the company's financing strategy, its approach to drug development and what's next for its clinical pipeline.
To learn more about the topics in this episode:
- ‘There is always a first’: Why US biotech Axiom will begin its IPO journey in Hong Kong (https://www.fiercebiotech.com/biotech/axiom-plans-head-nasdaq-hong-kong)
- Why Axiom hopes it’s ‘solved 2 major potholes’ that have hurt other stem cell biotechs (https://www.fiercebiotech.com/research/axioms-wharton-jelly-stem-cell-therapy-posts-positive-phase-1-data-newborn-brain-injury)
See omnystudio.com/listener (https://omnystudio.com/listener) for privacy information.